Drug intelligence / Profile preview

Eubio Isoquercetin

Development stage
Preclinical
Lead developer
Alps Pharmaceutical Industry
Modality
Small Molecules
Administration
Oral
01

Overview

Eubio Isoquercetin is a proprietary water-soluble formulation of **isoquercetin** developed by ALPS Pharmaceutical that is designed to improve the poor aqueous solubility and oral absorption of conventional isoquercetin. Isoquercetin is a naturally occurring flavonoid glycoside derived from *Sophora japonica* and has been studied as a small-molecule inhibitor of **protein disulfide isomerase**, a mechanism proposed to reduce thrombosis risk and potentially modulate thromboinflammatory pathways. The Eubio formulation uses all-natural food ingredients and reportedly achieves substantially higher quercetin exposure than ordinary isoquercetin without enzymatic modification, enabling lower doses versus standard isoquercetin preparations. The product appears to sit at the boundary between a drug-like nutraceutical and dietary supplement ingredient rather than a clearly approved pharmaceutical medicine.

Brand names
Eubio IsoquercetinEubioQuercetin
Other names
water-soluble isoquercetinisoquercetinquercetin-3-O-glucosidequercetin3-O-glucosidequercetin 3-O-glucoside
02

Targets

P4HB (Protein disulfide-isomerase)

Beyond the preview

Go deeper on Eubio Isoquercetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eubio Isoquercetin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call